1887

Abstract

The susceptibility of 62 isolates of in its mycelial form, from Latin-American countries (Peru, Venezuela, Brazil and Uruguay) and Spain, to amphotericin B (AB), itraconazole (IZ), posaconazole (PZ) and terbinafine (TB) was determined by measuring the MICs and minimum fungicidal concentrations (MFCs) using a standardized Clinical and Laboratory Standards Institute method. In general, TB was the most active drug, with the lowest geometric mean (GM) MIC and MFC values amongst isolates from the five countries tested. IZ and PZ showed almost the same activity against all strains tested, except for isolates from Uruguay where IZ gave the highest GM MIC (10.68 mg l). AB showed the widest MIC range (0.03–16.0 mg l); however, this drug was less active against 79 % of isolates (MICs above 1 mg l). MFCs were 5 to 20 times higher than the MICs, but the lowest GM MFC and range values were found for TB. IZ and PZ gave the highest GM MFC. MFC may be a better predictor of therapeutic response than MIC, especially in immunosuppressed patients, making the use of IZ and PZ an inappropriate treatment. There were some differences in susceptibility according to the geographical source of the isolates, with the MIC being lower for TB in Venezuelan strains (=0.066) and the MFC higher for PZ in Peruvian strains (=0.02). Thus, geographical origin may be important for appropriate treatment, and may relate to the identification of species of the complex.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.007609-0
2009-12-01
2019-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jmm/58/12/1607.html?itemId=/content/journal/jmm/10.1099/jmm.0.007609-0&mimeType=html&fmt=ahah

References

  1. Alvarado-Ramírez, E. & Torres-Rodríguez, J. M. ( 2007; ). In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods. Antimicrob Agents Chemother 51, 2420–2423.[CrossRef]
    [Google Scholar]
  2. Baker, J. H., Goodpasture, H. C., Kuhns, H. R., Jr & Rinaldi, M. G. ( 1989; ). Fungemia caused by an amphotericin B-resistant isolate of Sporothrix schenckii. Successful treatment with itraconazole. Arch Pathol Lab Med 113, 1279–1281.
    [Google Scholar]
  3. Bonifaz, A., Saúl, A., Paredes-Solis, V., Fierro, L., Rosales, A., Palacios, C. & Araiza, J. ( 2007; ). Sporotrichosis in childhood: clinical and therapeutic experience in 25 patients. Pediatr Dermatol 24, 369–372.[CrossRef]
    [Google Scholar]
  4. Chapman, S. W., Pappas, P., Kauffman, C., Smith, E. B., Dietze, R., Tiraboschi-Foss, N., Restrepo, A., Bustamante, A. B., Opper, C. & other authors ( 2004; ). Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day−1) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 47, 62–68.[CrossRef]
    [Google Scholar]
  5. Ellis, D. ( 2002; ). Amphotericin B: spectrum and resistance. J Antimicrob Chemother 49, 7–10.
    [Google Scholar]
  6. Espinel-Ingroff, A., Fothergill, A., Meter, J., Rinaldi, M. G. & Walsh, T. J. ( 2002; ). Testing conditions for determination of minimum fungicidal concentrations to new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 40, 3204–3208.[CrossRef]
    [Google Scholar]
  7. Kauffman, C. A. ( 1995; ). Old and new therapies for sporotrichosis. Clin Infect Dis 21, 981–985.[CrossRef]
    [Google Scholar]
  8. Kohler, L. M., Hamdan, J. S. & Ferrari, T. C. ( 2007; ). Successful treatment of a disseminated Sporothrix schenckii infection and in vitro analysis for antifungal susceptibility testing. Diagn Microbiol Infect Dis 58, 117–120.[CrossRef]
    [Google Scholar]
  9. Kosinski, R. M., Axelrod, P., Rex, J. H., Burday, M., Sivaprasad, R. & Wreiole, A. ( 1992; ). Sporothrix schenckii fungemia without disseminated sporotrichosis. J Clin Microbiol 30, 501–503.
    [Google Scholar]
  10. Marimon, R., Cano, J., Gené, J., Sutton, D. A., Kawasaki, M. & Guarro, J. ( 2007; ). Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol 45, 3198–3206.[CrossRef]
    [Google Scholar]
  11. Marimon, R., Serena, C., Gené, J., Cano, J. & Guarro, J. ( 2008; ). In vitro susceptibilities of five species of Sporothrix. Antimicrob Agents Chemother 52, 732–734.[CrossRef]
    [Google Scholar]
  12. McGinnis, M. R., Nordoff, N., Li, R. K., Pasarell, L. & Warnock, D. W. ( 2001; ). Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med Mycol 39, 369–371.[CrossRef]
    [Google Scholar]
  13. Mesa-Arango, A. C., Reyes-Montes, M. R., Pérez-Mejía, A., Navarro-Barranco, H., Souza, V., Zúñiga, G. & Toriello, C. ( 2002; ). Phenotyping and genotyping of Sporothrix schenckii isolates according to geographic origin and clinical form of sporotrichosis. J Clin Microbiol 40, 3004–3011.[CrossRef]
    [Google Scholar]
  14. NCCLS ( 2002; ). Reference Methods for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, approved guideline M38-A. Wayne, PA: National Committee for Clinical Laboratory Standards.
  15. Neyra, E., Fonteyne, P. A., Swinne, D., Fauche, F., Bustamante, B. & Nolard, N. ( 2005; ). Epidemiology of human sporotrichosis investigated by amplified fragment length polymorphism. J Clin Microbiol 43, 1348–1352.[CrossRef]
    [Google Scholar]
  16. Pappas, P. G., Tellez, I., Deep, A. E., Nolasco, D., Holgado, W. & Bustamante, B. ( 2000; ). Sporotrichosis in Peru: description of an area of hyperendemicity. Clin Infect Dis 30, 65–70.[CrossRef]
    [Google Scholar]
  17. Ramos-e-Silva, M., Vasconcelos, C., Carneiro, S. & Cestari, T. ( 2007; ). Sporotrichosis. Clin Dermatol 25, 181–187.[CrossRef]
    [Google Scholar]
  18. Scheinfeld, N. ( 2007; ). A review of the new antifungals: posaconazole, micafungin, and anidulafungin. J Drugs Dermatol 6, 1249–1251.
    [Google Scholar]
  19. Vilela, R., Souza, G. F., Fernandez Cota, G. & Mendoza, L. ( 2007; ). Cutaneous and meningeal sporotrichosis in a HIV patient. Rev Iberoam Micol 24, 161–163.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.007609-0
Loading
/content/journal/jmm/10.1099/jmm.0.007609-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error